IBDEI15F ; ; 01-FEB-2022
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;FEB 01, 2022
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,999) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,18649,1,4,0)
 ;;=4^I50.810
 ;;^UTILITY(U,$J,358.3,18649,2)
 ;;=^5151384
 ;;^UTILITY(U,$J,358.3,18650,0)
 ;;=I50.811^^64^833^63
 ;;^UTILITY(U,$J,358.3,18650,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18650,1,3,0)
 ;;=3^Heart Failure,Right,Acute
 ;;^UTILITY(U,$J,358.3,18650,1,4,0)
 ;;=4^I50.811
 ;;^UTILITY(U,$J,358.3,18650,2)
 ;;=^5151385
 ;;^UTILITY(U,$J,358.3,18651,0)
 ;;=I50.812^^64^833^65
 ;;^UTILITY(U,$J,358.3,18651,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18651,1,3,0)
 ;;=3^Heart Failure,Right,Chronic
 ;;^UTILITY(U,$J,358.3,18651,1,4,0)
 ;;=4^I50.812
 ;;^UTILITY(U,$J,358.3,18651,2)
 ;;=^5151386
 ;;^UTILITY(U,$J,358.3,18652,0)
 ;;=I50.813^^64^833^64
 ;;^UTILITY(U,$J,358.3,18652,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18652,1,3,0)
 ;;=3^Heart Failure,Right,Acute on Chronic
 ;;^UTILITY(U,$J,358.3,18652,1,4,0)
 ;;=4^I50.813
 ;;^UTILITY(U,$J,358.3,18652,2)
 ;;=^5151387
 ;;^UTILITY(U,$J,358.3,18653,0)
 ;;=I21.A1^^64^833^72
 ;;^UTILITY(U,$J,358.3,18653,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18653,1,3,0)
 ;;=3^Myocardial Infarction,Type 2
 ;;^UTILITY(U,$J,358.3,18653,1,4,0)
 ;;=4^I21.A1
 ;;^UTILITY(U,$J,358.3,18653,2)
 ;;=^5151374
 ;;^UTILITY(U,$J,358.3,18654,0)
 ;;=I48.11^^64^833^46
 ;;^UTILITY(U,$J,358.3,18654,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18654,1,3,0)
 ;;=3^Atrial Fibrillation,Longstanding Persistent
 ;;^UTILITY(U,$J,358.3,18654,1,4,0)
 ;;=4^I48.11
 ;;^UTILITY(U,$J,358.3,18654,2)
 ;;=^5158046
 ;;^UTILITY(U,$J,358.3,18655,0)
 ;;=I48.19^^64^833^44
 ;;^UTILITY(U,$J,358.3,18655,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18655,1,3,0)
 ;;=3^Atrial Fibrillation,Chr Persistent
 ;;^UTILITY(U,$J,358.3,18655,1,4,0)
 ;;=4^I48.19
 ;;^UTILITY(U,$J,358.3,18655,2)
 ;;=^5158047
 ;;^UTILITY(U,$J,358.3,18656,0)
 ;;=I48.20^^64^833^45
 ;;^UTILITY(U,$J,358.3,18656,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18656,1,3,0)
 ;;=3^Atrial Fibrillation,Chr Unspec
 ;;^UTILITY(U,$J,358.3,18656,1,4,0)
 ;;=4^I48.20
 ;;^UTILITY(U,$J,358.3,18656,2)
 ;;=^5158048
 ;;^UTILITY(U,$J,358.3,18657,0)
 ;;=I48.21^^64^833^48
 ;;^UTILITY(U,$J,358.3,18657,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18657,1,3,0)
 ;;=3^Atrial Fibrillation,Permanent
 ;;^UTILITY(U,$J,358.3,18657,1,4,0)
 ;;=4^I48.21
 ;;^UTILITY(U,$J,358.3,18657,2)
 ;;=^304710
 ;;^UTILITY(U,$J,358.3,18658,0)
 ;;=Z79.82^^64^833^71
 ;;^UTILITY(U,$J,358.3,18658,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18658,1,3,0)
 ;;=3^Long Term (Current) Use of Aspirin
 ;;^UTILITY(U,$J,358.3,18658,1,4,0)
 ;;=4^Z79.82
 ;;^UTILITY(U,$J,358.3,18658,2)
 ;;=^5063340
 ;;^UTILITY(U,$J,358.3,18659,0)
 ;;=Z79.01^^64^833^69
 ;;^UTILITY(U,$J,358.3,18659,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18659,1,3,0)
 ;;=3^Long Term (Current) Use of Anticoagulants
 ;;^UTILITY(U,$J,358.3,18659,1,4,0)
 ;;=4^Z79.01
 ;;^UTILITY(U,$J,358.3,18659,2)
 ;;=^5063330
 ;;^UTILITY(U,$J,358.3,18660,0)
 ;;=Z79.02^^64^833^70
 ;;^UTILITY(U,$J,358.3,18660,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18660,1,3,0)
 ;;=3^Long Term (Current) Use of Antithrombotics/Antiplatelets
 ;;^UTILITY(U,$J,358.3,18660,1,4,0)
 ;;=4^Z79.02
 ;;^UTILITY(U,$J,358.3,18660,2)
 ;;=^5063331
 ;;^UTILITY(U,$J,358.3,18661,0)
 ;;=E87.8^^64^834^12
 ;;^UTILITY(U,$J,358.3,18661,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,18661,1,3,0)
 ;;=3^Electrolyte/Fluid Balance Disorders NEC
 ;;^UTILITY(U,$J,358.3,18661,1,4,0)
 ;;=4^E87.8
